CSPC Pharma gains approval for oseltamivir suspension in China

CSPC Pharmaceutical Group Limited (HKEX: 1093) announced that its Oseltamivir Phosphate for Suspension (0.36g) has secured drug registration approval from the National Medical Products Administration of the People's Republic of China. The drug has also passed the consistency evaluation of quality and efficacy for generic drugs. The product is an inhibitor of influenza virus neuraminidase, indicated for influenza A and B treatment and prevention. The approval allows CSPC Pharma to further enrich its product portfolio in the therapeutic area of anti-infectives. The Board of Directors of CSPC comprises Mr. CAI Dongchen as Chairman.